Viva Biotech's stock plummeted 7.04% during intraday trading on Tuesday, following the release of its 2025 financial results.

The company reported a rise in attributable profit to 219.8 million yuan from 167.3 million yuan a year prior, with earnings per share increasing to 0.09 yuan from 0.06 yuan. However, revenue slipped 13% to 1.73 billion yuan from 1.99 billion yuan in the previous fiscal year, indicating a decline in top-line growth despite improved profitability.

This mixed financial performance, with profit growth overshadowed by a significant revenue drop, likely contributed to investor concern and the subsequent sell-off in the stock.